The Global Center for Medical Innovation (GCMI) helps verify, validate and accelerate the development and commercialization of new medical technologies that save lives and improve patient care. From our Northyards and 14th Street facilities in midtown Atlanta, we help find the finish line for medtech innovations at any point on the pathway from bench to bedside.
Have a clinical partner?
Rigors increase in intensity based on predicate technologies or devices and the relative invasive nature of their use, adjacent to, in contact with, or invasive within the patient.
What we're working on
Take a look at a few of your GT peers working with GCMI.
Our history
More than two decades and hundreds of preclinical studies completed, GCMI remains an industry leader in medtech design, development, preclinical testing and bioskills training programs.
Funding support
GCMI has dedicated, annual funding for medtech innovation at Georgia Tech, specifically for projects we believe have high potential for successful commercialization.
Who We Help and How
We help individual clinician innovators, start up companies, engineers and scientists with university supported technologies, large and small medical technology customers including industry partners and health systems. Because medtech innovation is endlessly more rigorous than other types of new technology commercialization or advancement, our milestone driven process helps ensure our customers’ ideas achieve a capital efficient path to market from IP, market assessment, design, prototyping, testing and training.
GT Researchers and Faculty Working with GCMI
Scott Hollister, Patsy and Alan Dorris Endowed Chair in Pediatric Technology, Professor, BME
Hollister and his team of biomedical engineers collaborated with the Global Center for Medical Innovation (GCMI) so that GCMI and Children's Healthcare of Atlanta on Georgia's first 3D printed tracheal implant in a pediatric patient.
Omer Inan, Linda J. and Mark C. Smith Chair and Associate Professor, ECE
After an IV needle has been inserted into a vein, there are various factors that can cause it to leak, either just beneath the skin or even deeper, into surrounding tissues. This painful process of unintended leakage is called infiltration.
W. Hong Yeo, Associate Professor, Woodruff Faculty Fellow
Currently available digital stethoscopes are durable but expensive, bulky and heavy for pediatrics, not capable of continuously monitoring sounds and subject to cross contamination. Dr. Yeo'S wireless flexible technology flips the script.
Select Georgia Tech / GCMI Collaborations
More from our Georgia Tech news and features category, including Capstone Design course spotlights in which “Students work in teams to design, build, and test prototypes with real world applications.” GCMI has proudly supported Capstone Design teams since 2018.
Venture Funding for New, “University Bred” Medical Technologies: When It’s Time and What to Bring
If you’ve been following our funding series for innovators seeking to spin out new medical technologies from higher ed “environments” like Georgia Tech, you’ll have seen: The Top 5 Medtech and Life Science Funding Resources for GT Faculty, Researchers and Investigators – at Phase Zero, THE Place to Start, and Follow-On, for University Sourced…
The GCMI 2023 State of Medtech Design and Development Report Part 2
In part 1 of our 2023 State of Medtech Design and Development Report we discussed sensors, AI and the paradigm shift in regulatory strategy. Here in part 2, we dive into a persistent need for gap analysis, the importance of focusing on the unmet clinical need, the challenges of manufacturing at scale and investigate…
What to Do, Where to Go and Why for Newly Funded University-Based New Medical Technologies
You’re a university-based researcher, investigator, faculty member or perhaps even a student who has snagged your first funding for the earliest stage commercialization, design and development activities for your potential medical technology. You might even have completed the first activities with that funding and scored $100,000 or more in follow-on funding from GRA, SBIR, or…
The GCMI 2023 State of Medtech Design and Development Report: Part 1
Innovation in medical technologies is something of a paradox. On one hand, new technologies that drive innovation can manifest at breakneck speed. On the other hand, the pace at which those technologies breed innovations that reach full commercialization and patient impact can be glacial by comparison. What have been the most significant changes with…
THE Place to Start, And Follow-On, For University-Sourced Medtech Innovation Funding
A dive into the Georgia Research Alliance (GRA) and its funding programs with GRA VP of Venture Development Ashley Cornelison In the first of this short series on medtech innovation funding opportunities, GCMI Director of Scientific Affairs Evan Goldberg stated, “GRA is the first place to go for those trying to commercialize a technology out…
The Top Five Medtech and Life Science Funding Sources for GT Faculty, Researchers, Investigators – AT PHASE ZERO
Atlanta is a burgeoning center of medtech and life science innovation. Georgia Tech faculty, researchers and students are measurable contributors to that ecosystem. Medtech innovation and the commercialization that creates real impact in provision of care, improved outcomes and value is replete with requirements and pitfalls that can doom ideas and technologies with high…
GCMI’s History
In the late 1990s, Dr. Robert Matheny, Chief Scientific Officer of CorMatrix Cardiovascular Inc., was looking for accessible resources, including preclinical support, needed to support innovation in care for cardiovascular physicians and their patients.
In 1999, his collaboration with other Atlanta area interventional cardiologists and cardiothoracic surgeons resulted in the development of a preclinical CRO called American Cardiovascular Research Institute which later became Translational Testing and Training Laboratories, Inc. or T3 Labs.
GCMI was founded in 2012 by Tiffany Wilson, now CEO of the Philadelphia Science Center. In 2016 GCMI became a Georgia Tech affiliate and acquired responsibility for T3 Labs making GCMI an end-to-end medtech innovation center.
More than two decades and hundreds of preclinical studies completed, GCMI remains an industry leader in medtech design, development, preclinical testing and bioskills training programs. We have helped more than 50 new medical technologies achieve regulatory approval.
Sherry Farrugia, who most recently served as executive director of Georgia Tech Pediatric Technologies, now serves as CEO of GCMI. She is the 2023 recipient of the Global Center for Health Innovation’s highest honor, the Industry Growth Award.
On Funding and Clinical Partners
We've got some funding for promising medical technologies.
GCMI has dedicated, annual funding for medtech innovation at Georgia Tech, specifically for projects we believe have high potential for successful commercialization, follow-on funding and improved patient outcomes. Funded projects are selected by GCMI leadership inclusive of consultation with the board of directors.
You've found a clinical partner. Now what?
New medical technologies are subject to the significant, necessary rigors applied by regulatory bodies and, ultimately, market forces. Those rigors increase in intensity based on predicate technologies or devices and the relative invasive nature of their use, adjacent to, in contact with, or invasive within the patient.
Get in touch. It's never too early.
If you want to know more about medtech innovation at Georgia Tech including who we are, what we do and how we do it, contact GCMI Director of Scientific Affairs Evan Goldberg via email evan.goldberg@t3labs.org.
More To Know
Phase Zero: The place to start for your new medical technology or idea.
Doing the right things early and following a rigorous phase gated process can substantially increase the likelihood of milestone achievement at any point in a technology’s commercialization pathway.
